Cargando…
Mechanistic understanding of the role of ATRX in senescence provides new insight for combinatorial therapies with CDK4 inhibitors.
Senescence is an irreversible form of growth arrest and is generally considered a favorable outcome of cancer therapies, yet little is known about the molecular events that distinguish this state from readily reversible growth arrest (i.e. quiescence). Recently, we discovered that during therapy ind...
Autores principales: | Kovatcheva, Marta, Klein, Mary E., Tap, William D., Koff, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791849/ https://www.ncbi.nlm.nih.gov/pubmed/29404388 http://dx.doi.org/10.1080/23723556.2017.1384882 |
Ejemplares similares
-
ATRX is a regulator of therapy induced senescence in human cells
por: Kovatcheva, Marta, et al.
Publicado: (2017) -
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
por: Kovatcheva, Marta, et al.
Publicado: (2015) -
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
por: Klein, Mary E., et al.
Publicado: (2018) -
Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on “Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity” by Garbarino et al.
por: Zalenski, Abigail A, et al.
Publicado: (2021) -
Structural and mechanistic insights into ATRX-dependent and -independent functions of the histone chaperone DAXX
por: Hoelper, Dominik, et al.
Publicado: (2017)